Skip to main content

Clinical Trials › NCT05925049

Active, Not Recruiting

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Sponsored by Biogen

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
400
Target enrollment
1
U.S. states
Jun 2023
Start date
Mar 2026
Expected completion

Interventions / Treatments

Natalizumab

Conditions studied

Multiple Sclerosis

Where this trial is running (1 site)

Cambridge

MS centers in Massachusetts

Compare treatment centers near a trial site by center type, providers and trials.

View Massachusetts centers
The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play